BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37201797)

  • 1. Increased CMV disease and "severe" BK viremia with belatacept vs. sirolimus three-drug maintenance immunosuppression.
    Petrossian G; Ortiz J; Ortiz AC; Addonizio K; Hsiao A; James R; Koizumi N; Patel S; Plews R
    Transpl Immunol; 2023 Aug; 79():101857. PubMed ID: 37201797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
    Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens.
    Chiodo Ortiz A; Petrossian G; Addonizio K; Hsiao A; Koizumi N; Yu Y; Plews R; Conti D; Ortiz J
    Transpl Immunol; 2023 Feb; 76():101774. PubMed ID: 36528248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of belatacept and tacrolimus on cytomegalovirus viral load control and relapse in moderate and high-risk cytomegalovirus serostatus kidney transplant recipients.
    Magua W; Johnson AC; Karadkhele GM; Badell IR; Vasanth P; Mehta AK; Easley KA; Newell KA; Rickert JB; Larsen CP
    Transpl Infect Dis; 2022 Dec; 24(6):e13983. PubMed ID: 36321801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept.
    Karadkhele G; Hogan J; Magua W; Zhang W; Badell IR; Mehta A; Lyon M; Pastan S; Pearson TC; Larsen CP
    Am J Transplant; 2021 Jan; 21(1):208-221. PubMed ID: 32519434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients.
    Tohme FA; Kalil RS; Thomas CP
    Transpl Infect Dis; 2015 Feb; 17(1):66-72. PubMed ID: 25582442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors and outcome in BK virus nephropathy in a Hispanic kidney transplant population.
    Pérez-Torres D; Bertrán-Pasarell J; Santiago-Delpín E; González-Ramos M; Medina-Mangual S; Morales-Otero L; González-Caraballo Z
    Transpl Infect Dis; 2010 Feb; 12(1):16-22. PubMed ID: 19804584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of BK viremia is associated with a lower risk of subsequent cytomegalovirus infection in kidney transplant recipients.
    Jorgenson MR; Descourouez JL; Lyu B; Astor BC; Saddler CM; Mandelbrot DA; Parajuli S
    Clin Transplant; 2020 Mar; 34(3):e13798. PubMed ID: 31994787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Risk Factors of BK Viremia and Clinical Impact of BK Virus Surveillance on Outcomes in Kidney Transplant Recipients: A Single-Center Cross-Sectional Study.
    Ji J; Feng S; Jiang Y; Wang W; Zhang X
    Exp Clin Transplant; 2019 Dec; 17(6):727-731. PubMed ID: 30995893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of sirolimus in patients with recurrent cytomegalovirus infection after kidney transplantation: A retrospective case series analysis.
    Shendi AM; Hung RKY; Caplin B; Griffiths P; Harber M
    Saudi J Kidney Dis Transpl; 2019; 30(3):606-614. PubMed ID: 31249224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of polyomavirus BK replication and impact of preemptive immunosuppression reduction in renal-transplant recipients in China: a 5-year single-center analysis.
    Huang G; Wang CX; Zhang L; Fei JG; Deng SX; Qiu J; Li J; Chen GD; Fu Q; Chen LZ
    Diagn Microbiol Infect Dis; 2015 Jan; 81(1):21-6. PubMed ID: 25445121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Factors of BK Virus Development in Kidney Transplant Recipients and the Effect of Low-Dose Tacrolimus Plus Everolimus on Clinical Outcomes.
    Yilmaz VT; Kisaoglu A; Avanaz A; Dandin O; Ozel D; Mutlu D; Akkaya B; Aydinli B; Kocak H
    Exp Clin Transplant; 2023 Sep; 21(9):727-734. PubMed ID: 37885288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
    Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy.
    Saad ER; Bresnahan BA; Cohen EP; Lu N; Orentas RJ; Vasudev B; Hariharan S
    Transplantation; 2008 Mar; 85(6):850-4. PubMed ID: 18360267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of renal function after the first year of follow-up in kidney transplant recipients treated for significant BK polyomavirus infection or BK polyomavirus-associated nephropathy.
    Simard-Meilleur MC; Bodson-Clermont P; St-Louis G; Pâquet MR; Girardin C; Fortin MC; Cardinal H; Hébert MJ; Lévesque R; Renoult E
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28207975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BK polyomavirus infection after renal transplantation: Surveillance in a resource-challenged setting.
    Bagchi S; Gopalakrishnan V; Srivastava SK; Upadhayay A; Singh G; Bhowmik D; Mahajan S; Dinda A; Agarwal SK
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28834032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BK viremia surveillance after kidney transplant: single-center experience during a change from cyclosporine-to lower-dose tacrolimus-based primary immunosuppression regimen.
    Geddes CC; Gunson R; Mazonakis E; Wan R; Thomson L; Clancy M; Carman WF
    Transpl Infect Dis; 2011 Apr; 13(2):109-16. PubMed ID: 21457419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept.
    Chavarot N; Divard G; Scemla A; Amrouche L; Aubert O; Leruez-Ville M; Timsit MO; Tinel C; Zuber J; Legendre C; Anglicheau D; Sberro-Soussan R
    Am J Transplant; 2021 Jul; 21(7):2448-2458. PubMed ID: 33283406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BK viremia surveillance and outcomes in simultaneous pancreas-kidney transplant recipients.
    Westphal SG; Lyden ER; Langewisch ED; Miles CD
    Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28509373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.